Navigation Links
Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
Date:8/4/2009

tly in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relation Contacts:

    Oramed Pharmaceuticals
    Tara Horn
    USA: +1-646-240-4193
    Int'l: +972-54-334-318
    Office: +972-2-566-0001
    Email: tara@oramed.com




'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
2. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
3. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
4. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
5. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
6. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
7. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
8. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
9. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
10. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... The National Necrotizing Fasciitis Foundation ... by doctors at Vanderbilt University Hospital in ... and Dr. John Crew , director of the ... Center in Daly City, CA. ... pioneered by Dr. Crew, that had previously saved the ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual list of the ... 1,361 in growth for the three years through 2014. Being named to the Inc. ... organizations in the country. , “We are thrilled to make the Inc. 5000 ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation (NYSE: ... today the closing of its previously announced public offering ... the underwriters of their option to purchase an additional ... price of $41.00 per share.  The exercise of the ... common stock sold by Intrexon to 5,609,756 shares and ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... , , , Ni-NTA Superflow ... protein preparations to be performed in parallel on the BioRobot 3000 , ... starting material, , up to 15 mg protein ... conditions using ready-to-run protocols. The increase in yield means that , ...
... , , , , ... efficient gene silencing in eukaryotic cell culture by ... RNA interference (RNAi), enables targeted , gene silencing ... siRNA oligonucleotide synthesis service that includes a range of modifications , ...
... , , , The LiquiChip Human ... provide fast and accurate quantification of a range of cytokines and , ... multiplex assay of 10 different cytokines using bead-based xMAP technology. , ... kinases , without using radioactivity. , ...
Cached Biology Technology:Ni-NTA Superflow Columns - automated large-scale purification of 6xHis-tagged , proteins 2Ni-NTA Superflow Columns - automated large-scale purification of 6xHis-tagged , proteins 3Ni-NTA Superflow Columns - automated large-scale purification of 6xHis-tagged , proteins 4Custom and library siRNA for efficient gene silencing 2Custom and library siRNA for efficient gene silencing 3Custom and library siRNA for efficient gene silencing 4Custom and library siRNA for efficient gene silencing 5LiquiChip Kits for bead-based cytokine and kinase assays 2LiquiChip Kits for bead-based cytokine and kinase assays 3
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... the John Innes Centre will publish the first RNA sequence data ... They will release the data via a website to a ... was also used to crowdsource expertise during the 2011 E. ... will be able to access the RNA sequence and start to ...
... 13, 2012 The University of Illinois at Urbana-Champaign ... Science Foundation to develop ozone-resistance in corn. These strains have ... pollutants have caused in crop yield. A team at the ... Change (GEGC) research theme will lead the research. ...
... first bulb, heat has been a mostly undesirable byproduct of ... heat at the point of need, on the nanoscale, to ... created by the Rice labs of Michael Wong, Ramon Gonzalez ... Society journal ACS Nano makes use of materials ...
Cached Biology News:Crowdsourcing to kickstart comeback from ash dieback 2University of Illinois receives grant to study ozone resistance in corn 2Rice uses light to remotely trigger biochemical reactions 2Rice uses light to remotely trigger biochemical reactions 3Rice uses light to remotely trigger biochemical reactions 4
... Immunogen: Synthetic peptide derived from the ... Specificity: Specific for the junctophilin-1 ... mouse brain and skeletal muscle homogenates ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
Request Info...
Laminin beta-1/gamma-1 (612C10)...
HSV 1 IgM...
Biology Products: